Articles Tagged With:
-
Pneumonia Outbreak in China
A cluster of cases of pneumonia apparently caused by a novel coronavirus has emerged in China.
-
Tafenoquine for Malaria Prevention and Relapse Treatment
Tafenoquine is effective for the prevention of all species of malaria and can be used to prevent relapse of Plasmodium vivax and Plasmodium ovale. G6PD status should be evaluated prior to use.
-
Taming of the Flu: What’s New for 2020
The 2019-2020 flu season is already among us, and it is imperative that those healthcare practitioners on the frontline have current knowledge of prevention and treatment strategies. Both influenza A and B strains have been identified, and their predominance varies by region and age group.
-
Impact of Infectious Disease Consultation for Candidemia
A retrospective cohort study found that infectious disease consultation for patients with candidemia resulted in lower 90-day mortality. This was likely a result of strong adherence to guideline- and evidence-based management and the low number of patients who were not treated.
-
Treating Ebola Virus Infection
Two monoclonal antibody preparations have been demonstrated to significantly reduce mortality in patients with Ebola virus infection.
-
Preventing Ebola Virus Infection
In a scientific/public health triumph, the first vaccine for the prevention of Ebola virus infection has been approved. If administered prior to 10 days after exposure, its protective efficacy is 100%.
-
Ebola in Democratic Republic of the Congo: Confronting Potential Disaster
The second largest outbreak of Ebola virus infection has come under control.
-
Researchers Testing Stem Cell Therapy for Multiple Sclerosis
NIH is funding a comparison of FDA-approved drugs against experimental stem cell approach.
-
Efficacy of Vitamin C Infusion on Outcomes in Sepsis-Induced ARDS
In this randomized, double-blinded, placebo-controlled trial, intravenous vitamin C infusion did not influence a change in the modified Sequential Organ Failure Assessment score from the time of infusion to four days compared to placebo.
-
Longer Antibiotic Courses for Pneumonia Do Not Improve Outcomes, But Cause More Adverse Effects
Two-thirds of general medicine patients with pneumonia received excess antibiotic therapy, with 93.2% of the unnecessary duration occurring after hospital discharge. Excess antibiotic therapy did not improve mortality or morbidity outcomes, although each additional antibiotic day was associated with 3% increased odds of antibiotic-associated adverse drug events.